Retrophin restructuring news

Rare disease company Retrophin will consolidate its operations to San Diego and close its office in Cambridge, Mass., by year end. The company has about 135 employees, and will relocate select employees and hire replacements. The decision was a "strategic effort to centralize expertise and improve efficiency."

The company's marketed products include Thiola tiopronin, a small molecule reducing and complexing thiol compound, to prevent cystine (kidney) stone formation in patients with severe homozygous cystinuria; Cholbam cholic acid capsules to treat bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders; and Chenodal chenodeoxycholic acid, an epimer of ursodeoxycholic acid, to treat gallstones in patients for whom surgery poses an unacceptable health risk...